A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2017
At a glance
- Drugs DKN 01 (Primary) ; Paclitaxel; Pembrolizumab
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors HealthCare Pharmaceuticals Inc; Leap Therapeutics
- 06 Dec 2017 Planned number of patients changed from 152 to 224.
- 06 Dec 2017 Planned End Date changed from 1 Jan 2019 to 1 May 2019.
- 06 Dec 2017 Planned primary completion date changed from 1 Jan 2019 to 1 Feb 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History